Snake venom toxins from Cerastes deserti (CdV)

Snake venom toxins from Cerastes deserti, the Sahara Horned Viper, represent a complex pharmacological mixture of enzymes and non-enzymatic proteins that disrupt physiological homeostasis in victims. The venom's primary constituents include snake venom metalloproteinases (SVMPs), serine proteases, phospholipase A2 (PLA2) enzymes, and disintegrins, which collectively induce severe local tissue damage, systemic hemorrhage, and coagulopathy (WHO Snakebite Database; Journal of Proteomics, 2012). SVMPs are particularly significant for their role in degrading the vascular basement membrane, leading to spontaneous bleeding, while serine proteases like cerastobin act as thrombin-like enzymes to deplete fibrinogen (UniProt P14571; UniProt P14572). PLA2 isoforms contribute to the inflammatory response and can exhibit myotoxicity or neurotoxicity depending on their specific molecular structure (Toxicon, 2006). In clinical settings, these toxins are the direct targets of antivenom therapy, which utilizes purified antibodies to neutralize their enzymatic and binding activities (Clinical Toxicology, 2019). Beyond their toxicological impact, individual components of Cerastes deserti venom are extensively studied as lead compounds for the development of novel therapeutics targeting cardiovascular and hematological disorders (Frontiers in Pharmacology, 2020).

Other names

Cerastes deserti venomSahara Horned Viper venomCerastes cerastes toxinsCerastes cerastes deserti venomHorned Viper toxins

Neutralization of toxic enzymatic activity and molecular binding sites via antibody-mediated sequestration or competitive inhibition of active sites.